CSI Market
Sign In | Register

Artelo Biosciences Inc (ARTL) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ARTL quarterly Cash Flow →
Cash flow data covering Artelo Biosciences Inc–Aug 31 2021 offers a view into how Dec 31 2025's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Aug 31 2021)
Operating Activities
Income0.00
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation1.14
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Net Change In Fair Value Of Marketable Securities-
Increase Decrease In Prepaid Expenses And Other Current Assets-
Increase Decrease In Account Payable-
Marketable Securities Gain Loss-
Increase Decrease In Deferred Offering Costs-
Increase Decrease In Advances From Investors-
Net Gains Losses On Trading Marketable Securities-
Profit And Loss-12.88
Losses On Extinguishment Of Debt0.83
Loss On Extinguishment Of Debt Related Party0.33
Amortization Of Debt Discounts And Premiums0.15
Fair Value Of Derivative Liability0.06
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Receivables0.00
Accounts Payable1.59
Increase (Decrease) in Accrued Liabilities0.05
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.13
Other Working Capital0.00
Other Noncash Expense0.04
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.05
Discontinued operations0.00
Net Cash flow from Operating Activities-8.52
Investing Activities
Capital Expenditures0.19
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Investment In Available For Sale Securities-
Proceeds From Sale Of Available For Sales Securities-
Proceeds From Disposition Of Available For Sale Securities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-0.25
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.06
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.42
Long-term debt - repayments-0.02
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock6.28
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Collection Of Share Subscription Receivable-
Repayment To Shareholder-
Refund For Fractional Stock-
Proceeds From Issuance Of Debt Related Party0.19
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities6.87
Effect of exchange rate on cash flow-0.02
Discontinued operations0.00
Free Cash Flow-8.33
Total Cash Flow-1.74
4 historic quarters locked

Sign in to unlock the full Artelo Biosciences Inc cash flow history.

Sign In Create Free Account

About Artelo Biosciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 24, 2026
  • Source: artl_10k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001640334-26-000368

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License